Astellas Broadens Commitment to Clinical Trial Data Transparency
TOKYO, Feb. 2, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, "Astellas") announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an independent Web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel.
"Transparency in the conduct of clinical trials is an important issue for the scientific and medical community today," said Sef Kurstjens, M.D., Ph.D., chief medical officer of Astellas Pharma, Inc. "By making our clinical trial data more widely available, we further its potential to increase understanding of disease and, ultimately, to address the unmet needs of patients around the globe."
The site, www.clinicalstudydatarequest.com, was developed to enable researchers to request data from clinical studies and perform further research that could help advance medical science or improve patient care. A research proposal will be reviewed and approved by an independent review panel, and Astellas will not be involved in decisions made by the independent review panel. Astellas will provide access to anonymized patient-level data from interventional clinical trials in patients completed after January 2010 for products and indications that have been approved in the U.S. and/or in the E.U. An initial list of Astellas studies available appears on clinicalstudydatarequest.com, which will be updated regularly.
In addition, Astellas also recently revised and expanded its Global Policy on Clinical Trial Data Disclosure, which details the company's principles regarding registration of clinical trials, posting and publication of trial results and scientific community access to trial data. The policy is available at www.astellas.com/en/corporate/disclosure/clinicalstudies.html.
About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney diseases. For more information on Astellas Pharma Inc., please visit the company Web site at www.astellas.com/en.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
